Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep

Vaccine ◽  
2008 ◽  
Vol 26 (41) ◽  
pp. 5255-5262 ◽  
Author(s):  
Gema Lorenzo ◽  
Raquel Martín-Folgar ◽  
Fernando Rodríguez ◽  
Alejandro Brun
Vaccines ◽  
2020 ◽  
Vol 8 (1) ◽  
pp. 82 ◽  
Author(s):  
Elena López-Gil ◽  
Sandra Moreno ◽  
Javier Ortego ◽  
Belén Borrego ◽  
Gema Lorenzo ◽  
...  

In vitro neutralizing antibodies have been often correlated with protection against Rift Valley fever virus (RVFV) infection. We have reported previously that a single inoculation of sucrose-purified modified vaccinia Ankara (MVA) encoding RVFV glycoproteins (rMVAGnGc) was sufficient to induce a protective immune response in mice after a lethal RVFV challenge. Protection was related to the presence of glycoprotein specific CD8+ cells, with a low-level detection of in vitro neutralizing antibodies. In this work we extended those observations aimed to explore the role of humoral responses after MVA vaccination and to study the contribution of each glycoprotein antigen to the protective efficacy. Thus, we tested the efficacy and immune responses in BALB/c mice of recombinant MVA viruses expressing either glycoprotein Gn (rMVAGn) or Gc (rMVAGc). In the absence of serum neutralizing antibodies, our data strongly suggest that protection of vaccinated mice upon the RVFV challenge can be achieved by the activation of cellular responses mainly directed against Gc epitopes. The involvement of cellular immunity was stressed by the fact that protection of mice was strain dependent. Furthermore, our data suggest that the rMVA based single dose vaccination elicits suboptimal humoral immune responses against Gn antigen since disease in mice was exacerbated upon virus challenge in the presence of rMVAGnGc or rMVAGn immune serum. Thus, Gc-specific cellular immunity could be an important component in the protection after the challenge observed in BALB/c mice, contributing to the elimination of infected cells reducing morbidity and mortality and counteracting the deleterious effect of a subneutralizing antibody immune response.


2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Tasneem Anthony ◽  
Antoinette van Schalkwyk ◽  
Marco Romito ◽  
Lieza Odendaal ◽  
Sarah Jane Clift ◽  
...  

2012 ◽  
Vol 93 (3) ◽  
pp. 330-339 ◽  
Author(s):  
Mary Ellenbecker ◽  
Leila Sears ◽  
Ping Li ◽  
Jean-Marc Lanchy ◽  
J. Stephen Lodmell

2013 ◽  
Vol 159 (3) ◽  
pp. 535-546 ◽  
Author(s):  
Susanne Jäckel ◽  
Martin Eiden ◽  
Malte Dauber ◽  
Anne Balkema-Buschmann ◽  
Alejandro Brun ◽  
...  

PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e59210 ◽  
Author(s):  
Weidong Xu ◽  
Douglas M. Watts ◽  
Margaret C. Costanzo ◽  
Xiaolei Tang ◽  
Leon A. Venegas ◽  
...  

2018 ◽  
Vol 56 (6) ◽  
Author(s):  
I. K. Ragan ◽  
A. S. Davis ◽  
D. S. McVey ◽  
J. A. Richt ◽  
R. R. Rowland ◽  
...  

ABSTRACTRift Valley fever virus (RVFV) is a mosquito-borne, zoonotic virus that infects ruminants, including cattle, sheep, goats, camels, and buffalo. Multiplexing diagnostic assays that can simultaneously detect antibodies against multiple RVFV antigens offer a high-throughput test for disease surveillance and vaccine evaluations. We describe the improvement and evaluation of a previously developed fluorescence microsphere immunoassay (FMIA) for the detection of IgG and IgM antibodies against the RVFV glycoprotein (Gn) and the immunogenic nucleocapsid protein (Np). Well-characterized vaccinated and experimentally infected ruminant sera were used for the evaluation of the assay. Recombinant viral proteins were produced and then coupled to polystyrene magnetic beads for analysis using the Luminex MAGPIX system with xMAP technology. The FMIA was performed in parallel with virus neutralization tests. Our results revealed the highest median fluorescence intensity (MFI) values for the detection of IgG antibodies against RVFV Np, indicating that this antigen would be a good candidate for a screening assay. The Np and Gn targets could differentiate infected animals from animals vaccinated with a candidate subunit vaccine formulation based on the RVFV Gn and Gc proteins. The results presented in this report demonstrate that FMIA provides a rapid and robust serological diagnostic tool for the detection of antibodies against RVFV. The targets developed in this assay provide the basis for the development of a companion diagnostic test for an RVFV Gn/Gc subunit vaccine that is capable of differentiating infected from vaccinated animals (DIVA), as well as a multiplex serodiagnostic assay that can simultaneously screen for several ruminant diseases.


Sign in / Sign up

Export Citation Format

Share Document